HOF Capital
HOF Capital is a venture capital firm founded in 2016 and headquartered in New York, New York, with additional offices in London and Cairo. The firm specializes in investing in early-stage and later-stage start-ups, focusing primarily on technology sectors such as artificial intelligence, fintech, enterprise solutions, and biotechnology. HOF Capital aims to support entrepreneurs in developing innovative technologies that address significant social challenges. The firm invests in both B2B and B2B2C companies across various regions, including the United States, Canada, Western Europe, and Israel. With a commitment to partnering with ambitious entrepreneurs, HOF Capital plays a role in guiding companies from their initial ideas through to an initial public offering.
Top Stages
Past deals in Newfoundland
Sequence Bio
Seed Round in 2019
Sequence Bio is a biotechnology company focused on advancing drug discovery and development through genome therapy. Leveraging the unique genetic characteristics of isolated populations, particularly those in Newfoundland, the company collects DNA and health information to enhance the identification of drug targets. This approach aims to improve the treatment of complex and inherited diseases, ultimately addressing the high failure rate of drug candidates and expediting access to effective therapies for patients in need. By utilizing genetic insights, Sequence Bio seeks to transform the landscape of medicine and deliver better health outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.